376 related articles for article (PubMed ID: 9308559)
21. Expression of p53 and selected proliferative markers (Ki-67, MCM3, PCNA, and topoisomerase IIα) in borderline ovarian tumors: Correlation with clinicopathological features.
Ciepliński K; Jóźwik M; Semczuk-Sikora A; Gogacz M; Lewkowicz D; Ignatov A; Semczuk A
Histol Histopathol; 2018 Feb; 33(2):171-179. PubMed ID: 28493257
[TBL] [Abstract][Full Text] [Related]
22. Expression of bcl-2, p53 and Ki-67 in arsenical skin cancers.
Chang CH; Tsai RK; Chen GS; Yu HS; Chai CY
J Cutan Pathol; 1998 Oct; 25(9):457-62. PubMed ID: 9821074
[TBL] [Abstract][Full Text] [Related]
23. [Retrospective analysis of selected tumor markers (p53, PCNA, Ki67; DNA ploidy) and ultrastructure in patients with larynx carcinomas].
Golusiñski W; Szmeja Z; Olofsson J; Biczysko W; Krygier-Stojałzowska A; Majewski P
HNO; 1998 Mar; 46(3):233-40. PubMed ID: 9583028
[TBL] [Abstract][Full Text] [Related]
24. Evaluation of p53, PCNA, Ki-67, MDM2 and AgNOR in oral peripheral and central giant cell lesions.
Souza PE; Mesquita RA; Gomez RS
Oral Dis; 2000 Jan; 6(1):35-9. PubMed ID: 10673786
[TBL] [Abstract][Full Text] [Related]
25. Expression of mismatch repair enzymes, hMLH1 and hMSH2 is not associated with microsatellite instability and P53 protein accumulation in basal cell carcinoma.
Saetta AA; Aroni K; Stamatelli A; Lazaris AC; Patsouris E
Arch Dermatol Res; 2005 Sep; 297(3):99-107. PubMed ID: 16012876
[TBL] [Abstract][Full Text] [Related]
26. Immunohistochemical staining properties of PCNA, Ki-67, p53, beta-hCG and HPL in trophoblastic disease.
Ozbilim G; Karaburun SP; Zorlu G; Kaya R; Erdoğan G; Karaveli S
Eur J Gynaecol Oncol; 2000; 21(2):200-4. PubMed ID: 10843487
[TBL] [Abstract][Full Text] [Related]
27. Proliferating cell nuclear antigen (PCNA); prognostic value in the clinical recurrence of primary basal cell carcinoma.
Toth DP; Guenther LC; Shum DT
J Dermatol Sci; 1996 Jan; 11(1):36-40. PubMed ID: 8867765
[TBL] [Abstract][Full Text] [Related]
28. Clinical features and immunoexpression of p53, MIB-1 and proliferating cell nuclear antigen in adrenal neoplasms.
Martins AC; Cologna AJ; Tucci S; Suaid HJ; Falconi RA
J Urol; 2005 Jun; 173(6):2138-42. PubMed ID: 15879867
[TBL] [Abstract][Full Text] [Related]
29. Cell proliferation and p53 protein expressions in cutaneous epithelial neoplasms.
Onodera H; Nakamura S; Sugai T
Am J Dermatopathol; 1996 Dec; 18(6):580-8. PubMed ID: 8989929
[TBL] [Abstract][Full Text] [Related]
30. Expression of p53 protein, PCNA, and Ki-67 in osteosarcomas of bone.
Park HR; Park YK
J Korean Med Sci; 1995 Oct; 10(5):360-7. PubMed ID: 8750062
[TBL] [Abstract][Full Text] [Related]
31. The stromal reaction in basal cell carcinomas. A prerequisite for tumour progression and treatment strategy.
Bertheim U; Hofer PA; Engström-Laurent A; Hellström S
Br J Plast Surg; 2004 Jul; 57(5):429-39. PubMed ID: 15191824
[TBL] [Abstract][Full Text] [Related]
32. [Expression of cell proliferation and apoptosis biomarkers in skin spinocellular carcinoma and actinic keratosis].
Dornelas MT; Rodrigues MF; Machado DC; Gollner AM; Ferreira AP
An Bras Dermatol; 2009; 84(5):469-75. PubMed ID: 20098848
[TBL] [Abstract][Full Text] [Related]
33. MDM2 and p53 expression in gliomas: a multivariate survival analysis including proliferation markers and epidermal growth factor receptor.
Korkolopoulou P; Christodoulou P; Kouzelis K; Hadjiyannakis M; Priftis A; Stamoulis G; Seretis A; Thomas-Tsagli E
Br J Cancer; 1997; 75(9):1269-78. PubMed ID: 9155045
[TBL] [Abstract][Full Text] [Related]
34. Correlation of the standardized uptake value in FDG-PET with the expression level of cell-cycle-related molecular biomarkers in resected non-small cell lung cancers.
Nakamura H; Hirata T; Kitamura H; Nishikawa J
Ann Thorac Cardiovasc Surg; 2009 Oct; 15(5):304-10. PubMed ID: 19901884
[TBL] [Abstract][Full Text] [Related]
35. p53 protein expression and cell proliferation in non-neoplastic and neoplastic proliferative skin diseases.
Batinac T; Zamolo G; Jonjić N; Gruber F; Petrovecki M
Tumori; 2004; 90(1):120-7. PubMed ID: 15143984
[TBL] [Abstract][Full Text] [Related]
36. Expressions of p53, cyclinD1 and histopathological features in basal cell carcinomas.
Koseoglu RD; Sezer E; Eyibilen A; Aladag I; Etikan I
J Cutan Pathol; 2009 Sep; 36(9):958-65. PubMed ID: 19187116
[TBL] [Abstract][Full Text] [Related]
37. Immunohistochemical study of primary and recurrent basal cell and metatypical carcinomas of the skin.
Kazantseva IA; Khlebnikova AN; Babaev VR
Am J Dermatopathol; 1996 Feb; 18(1):35-42. PubMed ID: 8721589
[TBL] [Abstract][Full Text] [Related]
38. Keratoacanthoma versus squamous cell carcinoma. An immunohistochemical reappraisal of p53 protein and proliferating cell nuclear antigen expression in keratoacanthoma-like tumors.
Cain CT; Niemann TH; Argenyi ZB
Am J Dermatopathol; 1995 Aug; 17(4):324-31. PubMed ID: 8600793
[TBL] [Abstract][Full Text] [Related]
39. Immunoexpression of p53 and COX-2 in basal cell carcinoma.
Enache AO; Stepan AE; Mărgăritescu C; Pătraşcu V; Ciurea RN; Simionescu CE; Camen A
Rom J Morphol Embryol; 2018; 59(4):1115-1120. PubMed ID: 30845292
[TBL] [Abstract][Full Text] [Related]
40. p53, PCNA and Ki-67 expression in oral squamous cell carcinomas: the vagaries of fixation and microwave enhancement of immunocytochemistry.
Allison RT; Best T
J Oral Pathol Med; 1998 Oct; 27(9):434-40. PubMed ID: 9790097
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
